Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Scandinavian Journal of Statistics, Theory and Applications|July 14, 2022
Efficiency of Naive Estimators for Accelerated Failure Time Models under Length-Biased SamplingPourab Roy, Jason P Fine, Michael R Kosorok
Journal of Biopharmaceutical Statistics|January 5, 2023
Utility of propensity score-based Bayesian borrowing of external adult data in pediatric trials: A pragmatic evaluation through a case study in acute lymphoblastic leukemia (ALL)Antara Majumdar, Rebecca Rothwell, Gregory Reaman, et al.
Integrative Biology : Quantitative Biosciences From Nano to Macro|January 14, 2014
Response of single leukemic cells to peptidase inhibitor therapy across time and dose using a microfluidic deviceMichelle L Kovarik, Alexandra J Dickinson, Pourab Roy, et al.
Therapeutic Innovation & Regulatory Science|February 10, 2026
Evaluating Post-Progression Survival in the Context of Progression-Free Survival Benefits: A Revisit of the CodeBreaK200 DesignZhoujingpeng Wei, Yuanyuan Han, Luoying Yang, et al.
Clinical Trials (London, England)|March 11, 2020
Exploration of baseline patient-reported side effect bother from cancer therapyJessica K Roydhouse, Bellinda L King-Kallimanis, Pourab Roy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2022
FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic DiseaseM Naomi Horiba, Sandra J Casak, Pallavi S Mishra-Kalyani, et al.
Blood Advances|February 28, 2025
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemiaFarhad Ravandi, Sravanti Rangaraju, Hagop Kantarjian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2021
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or AlterationsLuckson N Mathieu, Erin Larkins, Oladimeji Akinboro, et al.
Blood Advances|May 7, 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDSAmy E DeZern, Sylvain Thepot, Stéphane De Botton, et al.
Pageof 1